Carboxyamidotriazole Orotate is under clinical development by Tactical Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Carboxyamidotriazole Orotate’s likelihood of approval (LoA) and phase transition for Glioblastoma Multiforme (GBM) took place on 28 Apr 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Carboxyamidotriazole Orotate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Carboxyamidotriazole Orotate overview
Carboxyamidotriazole orotate (CTO) is under development for the treatment of non-small cell lung cancer, head and neck cancer, metastatic colorectal cancer, glioblastoma multiforme, malignant glioma, prostate cancer and metastatic melanoma. It is administered orally. The drug candidate targets calcium-channel-mediated calcium influx. It was also under development for the treatment of age-related macular degeneration
It was under development for ovarian cancer, metastatic colorectal cancer, synovial sarcoma, renal Cell Carcinoma, synovial Sarcoma, leiomyosarcoma, squamous Non-Small Cell Lung Carcinoma, colon Carcinoma.
Tactical Therapeutics overview
Tactical Therapeutics operates in pharmaceutical and healthcare industry. It is headquartered in United States.
Quick View Carboxyamidotriazole Orotate LOA Data
|Highest Development Stage|